Who We Are
Byondis started its biopharmaceutical activities in 2007.
In 2012, the company became a new biopharmaceutical subsidiary and quickly built a promising pipeline of innovative research and development programs.
After becoming an independent company in November 2019, the biopharmaceutical company rebranded itself as Byondis in April 2020.
Byondis is a subsidiary of the holding company Byondis Holding B.V.
“Byondis’ ambition is to become a leading pharmaceutical company by discovering, developing and delivering proprietary breakthrough medicinal modalities to patients in the field of cancer and other difficult to treat diseases. “
Jacques Lemmens, PhD, Founder / Chairman of the Board
Leadership Team
Our management team has a broad scientific, clinical, operational and partnering experience.
Sustainability
We care – for each other, for partners, for patients and for society at large.
Partnering
To realize the full potential of our science, pipeline, and technology, we are open to collaborate and partner among research institutions and biopharmaceutical companies.
Pipeline
Our diverse pipeline of proprietary next-generation ADCs reflects our expertise in research, lead identification, preclinical/clinical development, process development and manufacturing.
Our Science
We employ the latest insights in tumor biology and immunology in our search for new molecular targets and development of new mechanisms for antibody-drug conjugates (ADCs) and small molecule programs.
